Description: The Health Section chairperson discusses the past year's activity, especially the Visions for the Future of the U.S. Health Care System essay contest, and an update on the Untapped Opportunities for Actuaries in Health initiative.

Description: A report on the proceedings of the June 2010 SOA health meeting. Leading topics included health care reform, opportunities to expand actuaries' roles, the global financial crisis, and collaboration with other organizations.

Description: Feature article discussing the findings of a recent CDC report and offering a challenge to actuaries in response to those findings.

Description: Health care reform will require health insurers to change the way they make decisions on what to sell while remaining financially sound. The new regulatory reality of expanded access to coverage leaves insurers with fewer options for managing costs and business risk. With the introduction of risk adjustment mechanisms in the exchanges, the most profitable members will not necessarily be the lowest cost ones, but rather, the members which the health plan is relatively more effective at servicing. While Patient Protection and Affordable Care Act 'PPACA' prohibits underwriting and using any health status information for denying coverage or varying the premium rates, this article describes how the use of consumer data will affect the way health insurers make decisions on what products to sell.

Description: Updates on the efforts of the Academy’s health practice council. its work groups and task forces, to educate and influence health care policymakers on issues including principles for health care reform, Medicare, wellness programs, and solvency.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: Highlights of health related articles from the North American Actuarial Journal. A paper on health care reform and efficiency is published in a recent issue of the NAAJ.

Description: The Society is taking a hard look at its members’ needs and our future as a profession. Two recent studies have focused attention on the building of our future: Report of the Task Force on the Future of the Actuary and Report of the Task Force on Strengthening the Profession. Both reports discuss the importance of our profession in health care matters. But, neither report is designed to address the practical issues involved with building toward our future in health care.

Description: The Society of Actuaries to fund a research proposal to investigate risk adjusters.

Description: Discussion of state medicaid expansion due to provisions of the Affordable Care Act.